Aspire Private Capital’s Inovio Pharmaceuticals INO Stock Holding History

Aspire Private Capital’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8	Closed	-$45	–	714
2023 Q2	$45	Hold	8	–	–	﹤0.01%	669
2023 Q1	$82	Hold	8	–	–	﹤0.01%	645
2022 Q4	$156	Hold	8	–	–	﹤0.01%	630
2022 Q3	$0	Hold	8	–	–	﹤0.01%	638
2022 Q2	$0	Hold	8	–	–	﹤0.01%	623
2022 Q1	$0	Hold	8	–	–	﹤0.01%	635
2021 Q4	$0	Hold	8	–	–	﹤0.01%	655
2021 Q3	$1K	Buy	+8	New	+$803	﹤0.01%	550
2021 Q1	–	Sell	-8	Closed	-$1K	–	570
2020 Q4	$1K	Hold	8	–	–	﹤0.01%	421
2020 Q3	$1K	Buy	+8	New	+$1.67K	﹤0.01%	424
2020 Q1	–	Sell	-8	Closed	–	–	361
2019 Q4	$0	Hold	8	–	–	﹤0.01%	512
2019 Q3	$0	Hold	8	–	–	﹤0.01%	502
2019 Q2	$0	Hold	8	–	–	﹤0.01%	576
2019 Q1	$0	Hold	8	–	–	﹤0.01%	581
2018 Q4	$0	Buy	+8	New	+$486	﹤0.01%	547

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aspire Private Capital's INO Position: Q3 2023 in Review

Aspire Private Capital sold out of Inovio Pharmaceuticals (INO) in Q3 2023, closing a stake of 8 shares — an estimated $45 sold.

Aspire Private Capital first reported a position in INO in Q4 2018 and held it in 15 quarters. The position peaked at $1K in Q3 2021. 124 funds tracked by Wall St. Rank hold INO as of Q3 2023.

Aspire Private Capital reported no remaining Inovio Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Aspire Private Capital sold 8 Inovio Pharmaceuticals shares in Q3 2023, an estimated $45.
Aspire Private Capital first reported a position in Inovio Pharmaceuticals in Q4 2018 and held it in 15 quarters.
Aspire Private Capital's Inovio Pharmaceuticals position peaked at $1K in Q3 2021.
124 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2023.

Based on Aspire Private Capital's 13F filing for Q3 2023, filed 3 Nov 2023.